Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study.

BACKGROUND Stroke is the third most common cause of cardiovascular disease death in patients on dialysis therapy; however, characteristics of cerebrovascular disease, including clinical subtypes and subsequent consequences, have not been well described. STUDY DESIGN Prospective national cohort study, the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. SETTINGS & PARTICIPANTS 1,041 incident dialysis patients treated in 81 clinics enrolled from October 1995 to July 1998, followed up until December 31, 2004. PREDICTOR Time from dialysis therapy initiation. OUTCOMES & MEASUREMENTS Cerebrovascular disease events were defined as nonfatal (hospitalized stroke and carotid endarterectomy) and fatal (stroke death) events after dialysis therapy initiation. Stroke subtypes were classified by using standardized criteria from the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) system. The incidence of cerebrovascular event subtypes was analyzed by using time-to-event analyses accounting for competing risk of death. Clinical outcomes after stroke were abstracted from medical records. RESULTS 165 participants experienced a cerebrovascular event with an overall incidence of 4.9 events/100 person-years. Ischemic stroke was the most common (76% of all 200 events), with cardioembolism subtype accounting for 28% of the 95 abstracted ischemic events. Median time from onset of symptoms to first stroke evaluation was 8.5 hours (25th and 75th percentiles, 1 and 42), with only 56% of patients successfully escaping death, nursing home, or skilled nursing facility. LIMITATIONS Relatively small sample size limits power to determine risk factors. CONCLUSIONS Cerebrovascular disease is common in dialysis patients, is identified late, and carries a significant risk of morbidity and mortality. Stroke etiologic subtypes on dialysis therapy are multifactorial, suggesting risk factors may change the longer one has end-stage renal disease. Additional studies are needed to address the poor prognosis through prevention, early identification, and treatment.

[1]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[2]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[3]  J. Bragg-Gresham,et al.  Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  M. J. Hall,et al.  2005 National Hospital Discharge Survey. , 2007, Advance data.

[5]  J. Griffith,et al.  Subcortical cognitive impairment in dialysis patients , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[6]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[7]  C. McIntyre,et al.  Vascular calcification and cardiovascular function in chronic kidney disease. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  S. Gutnikov,et al.  Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) , 2005, The Lancet.

[9]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[10]  S. Ibayashi,et al.  Stroke in patients on maintenance hemodialysis: a 22-year single-center study. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  K. D. Workgroup.  K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[13]  V. Coviello,et al.  Cumulative Incidence Estimation in the Presence of Competing Risks , 2004 .

[14]  N. Powe,et al.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.

[15]  B. Kestenbaum,et al.  Elevated risk of stroke among patients with end-stage renal disease. , 2003, Kidney international.

[16]  V. Vaccarino,et al.  Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. , 2003, Kidney international.

[17]  V. Feigin,et al.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century , 2003, The Lancet Neurology.

[18]  K. Sugimura,et al.  Silent Cerebral Infarction in Hemodialysis Patients , 2003, American Journal of Nephrology.

[19]  M. Rocco,et al.  Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  G. Savazzi,et al.  Cerebral Imaging Changes in Patients with Chronic Renal Failure Treated Conservatively or in Hemodialysis , 2001, Nephron.

[21]  Kelly R. Evenson,et al.  Prehospital and In-Hospital Delays in Acute Stroke Care , 2001, Neuroepidemiology.

[22]  C. Schmid,et al.  Comorbidity Assessment in Hemodialysis and Peritoneal Dialysis Using the Index of Coexistent Disease , 2000, Seminars in dialysis.

[23]  S. Ibayashi,et al.  Hemodialysis causes severe orthostatic reduction in cerebral blood flow velocity in diabetic patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  J. Blacher,et al.  Impact of aortic stiffness on survival in end-stage renal disease. , 1999, Circulation.

[25]  G. Russell,et al.  Sudden and cardiac death rates in hemodialysis patients. , 1999, Kidney international.

[26]  P. Singhal,et al.  Outcome of stroke in patients undergoing hemodialysis. , 1998, Archives of internal medicine.

[27]  L H Kuller,et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[28]  N. Powe,et al.  Choices for Healthy Outcomes In Caring for End Stage Renal Disease , 1996 .

[29]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[30]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[31]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.